Skip to main content

BioCommunique Article

Bringing you the latest financial and strategic news from top leaders in life science over the past two weeks.

Charles River Labs Acquires Citoxlab, Gossamer Goes Public, Genentech Partnership Could Generate $280 Million for Xencor

  • 2019-02-14T01:04:00.000+0000
  • California
  • Author: Lauren Panetta

2/13/19 | GEN
Charles River Labs to Acquire Citoxlab for $510M, Expanding Early-Stage CRO Activity

2/13/19 | STAT News
For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

2/12/19 | FierceBiotech
Boehringer, IBM link up for blockchain clinical trials in Canada

2/11/19 | FierceBiotech
AbbVie, Teneobio ink $90M deal to develop BCMA bispecific

2/8/19 | San Diego Union-Tribune
Gossamer Bio goes public; San Diego biotech valued at more than $1 billion

2/8/19 | FierceBiotech
Verily planning one-stop, high-tech campus for opioid rehab

2/7/19 | FierceBiotech
Alector and Stealth Bio aim high with pricings of their IPOs

2/7/19 | FierceBiotech
Galapagos continues fibrosis pipeline build-out with Evotec deal

2/6/19 | Sanofi
Sanofi: FDA approves Cablivi® (caplacizumab-yhdp), the first Nanobody®-based medicine, for adults with acquired thrombotic thrombocytopenic purpura (aTTP)

2/6/19 | GEN
Genentech to Develop Xencor IL-15 Cytokines in Immuno-Oncology Partnership

2/5/19 | GSK
GSK and Merck KGaA, Darmstadt, Germany announce global alliance to jointly develop and commercialise M7824, a novel immunotherapy with potential in multiple difficult-to-treat cancers

2/5/19 | FierceBiotech
Merck KGaA, GSK pen $4.2B biobucks pact for next-gen Bavencio

2/4/19 | Eli Lilly & Company
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

2/4/19 | GEN
argenx Plans Autoimmune Treatments Using Halozyme’s ENHANZE Drug-Delivery Technology

2/4/18 | San Diego Union-Tribune
Halozyme drug tech gets company $30 million upfront, possibly hundreds of millions more